Literature DB >> 15719392

Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.

Jong-Lyel Roh1, Myung-Whun Sung, Kwang Hyun Kim.   

Abstract

BACKGROUND: Tumor growth is accelerated in surgical wounds. However, few experiments seeking to prevent such accelerated tumor growth have been performed.
METHODS: We created surgical wounds in three syngeneic mice for the implantation of three murine cancer cell lines, SCC VII, CT-26, and B16F10. The tumor growth in the wound group was compared with that in non-wound-control mice. Celecoxib or indomethacin was administered to the mice that had tumor implanted into the surgical wound to observe the tumor-suppressive effect.
RESULTS: The surgical wounds promoted tumor growth with different degrees, depending on the type of tumor. Such an accelerated tumor growth did not seem to be affected by cyclooxygenase-2 expression of tumors per se, but its mechanism needs to be explained by further studies. Celecoxib and indomethacin had a significant inhibitory effect on the tumor growth in the surgical wound. This suppressive effect is most obvious when celecoxib is administered daily from 1 day before surgical wounding and tumor implantation.
CONCLUSION: Our results can justify that the preventive use of celecoxib in patients in whom local recurrence by tumor contamination is predicted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15719392     DOI: 10.1002/hed.20167

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  5 in total

1.  Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.

Authors:  C K Martin; W P Dirksen; M M Carlton; L G Lanigan; S P Pillai; J L Werbeck; J K Simmons; B E Hildreth; C A London; R E Toribio; T J Rosol
Journal:  Vet Comp Oncol       Date:  2013-05-08       Impact factor: 2.613

2.  Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.

Authors:  Clara Curiel-Lewandrowski; Susan M Swetter; Janine G Einspahr; Chiu-Hsieh Hsu; Ray Nagle; Paul Sagerman; Joseph Tangrea; Howard Parnes; David S Alberts; Hsiao-Hui Chow
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

3.  Assessment of the tumourigenic and metastatic properties of SK-MEL28 melanoma cells surviving electrochemotherapy with bleomycin.

Authors:  Vesna Todorovic; Gregor Sersa; Vid Mlakar; Damjan Glavac; Maja Cemazar
Journal:  Radiol Oncol       Date:  2012-01-12       Impact factor: 2.991

4.  Cell-line-specific stimulation of tumor cell aggressiveness by wound healing factors - a central role for STAT3.

Authors:  Lars Ekblad; Gustaf Lindgren; Emma Persson; Elisabeth Kjellén; Johan Wennerberg
Journal:  BMC Cancer       Date:  2013-01-25       Impact factor: 4.430

5.  Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer.

Authors:  Michael W Retsky; William J M Hrushesky; Isaac D Gukas
Journal:  BMC Cancer       Date:  2009-01-08       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.